BGC 200582

Drug Profile

BGC 200582

Alternative Names: BGC-20-0582

Latest Information Update: 21 Mar 2014

Price : $50

At a glance

  • Originator BTG
  • Class Antiparasitics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Pediculosis

Most Recent Events

  • 01 Jan 2013 Discontinued - Phase-II for Pediculosis in USA (Topical)
  • 02 Apr 2009 BTG is seeking partnership opportunities to further develop BGC 200582 for Pediculosis
  • 13 Dec 2007 BTG completes enrolment in its phase II trial for pediculosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top